Genetic testing to guide treatment for metastatic pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial uses advanced genetic testing on your tumor sample and lab-grown tumor 'organoids' to help pick treatments that may work better for your metastatic pancreatic cancer. The goal is to find a more personalized treatment plan for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have pancreatic cancer that has spread to other parts of the body (metastatic).
- You need to have a tumor that can be safely biopsied (a small piece removed for testing).
- You should be able to care for yourself (performance status 0-2) and have a life expectancy of more than 3 months.
- Your blood counts and kidney function need to be within certain limits.
- You must not have serious heart problems or be on blood thinners that can't be paused.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests a treatment approach using standard chemotherapy along with stem cells taken from you to treat metastatic pancreatic or breast cancer. It is mainly designed to check safety and find the best way to give the treatment, and it may offer an option for people whose cancer has spread.
This trial tests whether a blood test that detects tumor DNA can help doctors decide early if the standard chemotherapy is working, and if switching treatment might be better. It is for people newly diagnosed with metastatic pancreatic cancer who are starting their first chemotherapy.
This trial studies metastatic pancreatic cancer by taking a small tissue sample and analyzing its genes. It may help doctors better understand which cancer subtypes patients have, which can guide future treatment choices.
This study uses genetic testing of your tumor to find specific mutations and match you with targeted therapies, aiming to improve outcomes for advanced cancers with poor prognosis. If you have pancreatic, liver, or triple negative breast cancer and are starting treatment, this trial may help you access personalized treatment options.
This study looks at advanced or metastatic pancreatic cancer patients and uses stored tumor tissue to learn what may predict treatment outcomes. You may be able to join if you have had limited prior chemotherapy and can provide an archived tissue sample.
This study is looking at genetic material and proteins from pancreatic tumors to understand how the cancer responds to treatment. It aims to help doctors choose the best therapies for patients with certain types of pancreatic cancer that can be removed surgically or that have not spread to other organs.
Hear when a new Pancreatic Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.